

---

## Subject Index

### A

ABA model, 128-129  
A-band, 11  
ACTH, 110-114, 119  
Actin, 11-13  
Adrenal glands, 110, 114  
Anorexia nervosa, 123, 126, 127  
ATP metabolism, 43, 62  
ATP-generating activities, 51

### B

Baboon, 147, 152, 157  
 $\beta$ -oxidation, 62, 118

### C

$^{13}\text{C}$  MR spectroscopy ( $^{13}\text{C}$  MRS), 45, 49, 51-52  
cardiac steatosis, 58  
Carnitine acetyltransferase (CAT), 35  
Cell membrane, 17-21  
Clearance rate 91  
Central Nervous System (CNS), 9, 13, 36-37  
Contractile unit, 17-21  
cortisol, 110, 112-113, 119, 127, 129  
Corticotropin Releasing Hormone (CRH), 111-112, 115, 119, 128-129

### D

Doping, 120  
Doubly labeled water technique, 123-125, 127

### E

Eating behavior, 114, 127-128  
Ectopic fat, 56-57, 58, 59-60, 62

Electron transport, 116

Endomysium, 10

Energy balance, 37-38, 46, 48, 70, 109, 112, 117, 125-128

Energy expenditure, 112-114, 115-116, 123-128, 134, 137, 149-150, 152-157

Energy intake, 37-38, 112, 115, 125-126, 152

Epimysium, 10

### F

Fatty acids, 18, 33-37, 41

Free fatty acids, 69, 72, 100, 116, 118

### G

Genetic polymorphisms, 30

Glucocorticoids, 112-120

Glucose, 4-6, 20, 33-36, 41, 43, 48, 51, 57, 61, 69-70, 72-73, 86, 88-91, 100, 116-118, 134, 139

Glucose metabolism, 36-38, 51, 55, 57-58, 69, 77, 115, 148,

Glucose tolerance, 4, 58-59, 62, 104, 141

Impaired glucose tolerance (IGT), 134, 141, 59, 62, 103

Mitochondrial glucose, 69

Glycogen, 10, 43, 45, 51, 71, 116, 118, 136

Glycogenolysis, 43, 46, 50-51, 117

Glycolysis, 43, 48, 51, 68-69

Glycolytic flux, 50

### H

$^1\text{H}$  MR spectroscopy ( $^1\text{H}$  MRS), 44, 58

H-band, 11

- Homo Erectus, 2-4, 6  
Homocysteine, 31  
HPA axis, 109, 111-112, 114, 115, 118-119, 129  
Human evolution, 1-2  
Hypoleptinemia, 129  
Hyperactivity, 126-129  
Hypophysis, 109-111  
Hypothalamus, 36-38, 109-110, 113-114, 128, 129
- I**  
I-band, 11, 14  
In vivo Magnetic Resonance Spectroscopy (MRS), 44  
Inflammation, 73-74, 76-79, 99-105, 136, 142,  
Insulin receptor, 100, 115  
Insulin resistance, 4, 38, 40, 41, 55-56, 58-62, 68, 72, 74-79, 99-104, 119, 134, 136, 140-141, 148, 158,  
Insulin sensitivity, 4-5, 38, 44, 55-56, 58-59, 62, 76-77, 100, 103-104, 119, 134-135, 141, 148
- K**  
Krebs Cycle, 34, 43, 69
- L**  
Leptin, 36-39, 100, 102-103, 112-113, 128-129
- M**  
Mitochondrial function, 34, 41, 47, 59, 68, 70-77  
M-line, 12  
Myoblasts, 10  
Myosin, 11-15
- N**  
Nebulin, 13  
Needle biopsy, 68
- Non-alcoholic fatty liver disease, 57, 140  
Nucleotides, 29, 31
- O**  
obesity, 4-6, 37-38, 40, 55-56, 59-60, 62, 68, 72, 75-76, 79, 99-101, 104, 112-113, 116, 123-125, 136, 139-141, 147-149, 153, 157
- P**  
<sup>31</sup>P MR spectroscopy (<sup>31</sup>P MRS), 45-47, 59-60  
PCr breakdown, 51  
Perimysium, 10  
Pyruvate Dehydrogenase (PDH), 34, 69, 71-72, 74
- S**  
Sarcolemma, 10-11, 21  
Sarcomere, 9-13  
Sarcoplasm, 10,  
Sarcoplasmic reticulum, 10-11, 14-15, 71  
Smooth muscles, 9, 135,  
Steady State, 44, 46-47, 89-93, 95-97  
Striated muscles, 9, 11
- T**  
TCA cycle flux ( $V_{TCA}$ ), 45, 48-49  
Tinin, 12  
Tracer, 93-97,  
Tracer-based methods, 59, 85, 86  
Transverse tubules, 11  
Thrifty genotype, 4  
Tropomyosin, 13-15  
Troponin, 13-15  
Turnover rate, 92-93  
Type 2 diabetes, 4-6, 55-58, 61-62, 69, 75, 99, 114, 141, 147-148
- Z**  
Z-lines, 11